Myricx Bio
Myricx Bio formerly Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer. The company received an initial £4.5 million in seed financing from Sofinnova Partners and Brandon Capital Partners.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Live
Website
myricxpharma.com
Related News
Myricx Bio Further Strengthens its Clinical Team and US Presence with the Appointment of David Ellis as VP, Regulatory Affairs
Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development
Myricx Bio announces Board Changes
Myricx Bio announces £90m ($114m) Series A financing to advance its novel NMTi-ADC therapeutics into clinical development
Myricx Bio enters into an exclusive antibody license agreement with WuXi Biologics
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.